Advanced in Chronic Graft Versus Host Disease (cGvHD)

Dr. Antonio Di Stasi

Hematology Oncology | Hematology | Oncology
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
Accepting New Patients
Offers Telehealth
20 Years of Experience
Advanced in Chronic Graft Versus Host Disease (cGvHD)
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antonio Di Stasi is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Di Stasi has been practicing medicine for over 20 years and is rated as an Advanced provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Di Stasi is currently accepting new patients.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 1 clinical trial in the study of Chronic Graft Versus Host Disease (cGvHD).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug, Procedure
Study Drug: Fludarabine
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 3
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Enrollment Status: Unknown
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drug: EAGD T-cell
Study Phase: Phase 1
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
View 5 Less Clinical Trials

35 Total Publications

Low-dose decitabine plus venetoclax as post-transplant maintenance for high-risk myeloid malignancies.
Low-dose decitabine plus venetoclax as post-transplant maintenance for high-risk myeloid malignancies.
Journal: EJHaem
Published: January 26, 2024
Similar Doctors
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Susan Bal
Hematology Oncology | Hematology | Oncology
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Susan Bal
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (1.0 miles away)
205-934-3460
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susan Bal is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Bal is rated as a Distinguished provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bal is currently accepting new patients.

Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Omer H. Jamy
Hematology Oncology | Hematology | Oncology
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Omer H. Jamy
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Omer Jamy is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Jamy is rated as a Distinguished provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelogenous Leukemia (CML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jamy is currently accepting new patients.

Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Ibrahim N. Muhsen
Hematology Oncology
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Dr. Ibrahim N. Muhsen
Hematology Oncology
Birmingham, AL 
 (1.0 miles away)
Languages Spoken:
English
See accepted insurances

Ibrahim Muhsen is a Hematologist Oncology provider in Birmingham, Alabama. Dr. Muhsen is rated as an Experienced provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Acute Lymphoblastic Leukemia (ALL), Autoimmune Hemolytic Anemia, Bone Marrow Transplant, and Bone Graft.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Di Stasi's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile